ASH 2019: Initial results of a phase II study investigating combination immunotherapy for treatment of relapsed diffuse large b-cell lymphoma.
Home / Resource Library / Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study